Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells

Molecular Therapy

Volumn 16, Issue 2, 2008, Pages 269-279

  Han, Shuhong ^a   Wang, Bei ^a   Cotter, Matthew J ^a   Yang, Li Jun ^a   Zucali, James ^a   Moreb, Jan S ^a   Chang, Lung Ji ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALNEXIN; DENDRITIC CELL VACCINE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; LENTIVIRUS VECTOR; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LYSATE; CONTROLLED STUDY; DRUG MECHANISM; EFFECTOR CELL; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 38649098801     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300369     Document Type: Article

References (44)

1. Hideshima, T, Richardson, P and Anderson, KC (2003). Novel therapeutic approaches for multiple myeloma. Immunol Rev 194: 164-176.
2. Denz, U, Haas, PS, Wasch, R, Einsele, H and Engelhardt, M (2006). State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 42: 1591-1600.
3. Bellucci, R and Ritz J (2002). Allogeneic stem cell transplantation for multiple myeloma. Rev Clin Exp Hematol 6: 205-224.
4. Barlogie, B, Shaughnessy, J, Tricot, G, Jacobson, J, Zangari, M, Analssie, E et al. (2004). Treatment of multiple myeloma. Blood 103: 20-32.
5. Cavo, M and Baccarani, M (2006). The changing landscape of myeloma therapy. N Engl J Med 354: 1076-1078.
6. Raje, N, Hideshima, T, Davies, FE, Chauhan, D, Treon, SP, Young, G et al. (2004). Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 125: 343-352.
7. Bogen, B, Ruffini, PA, Corthay, A, Fredriksen, AB, Froyland, M, Lundin, K et al. (2006). Idiotype-specific immunotherapy in multiple myeloma: Suggestions for future directions of research. Haematologica 91: 941-948.
8. Houet, L and Veelken, H (2006). Active immunotherapy of multiple myeloma. Eur J Cancer 42: 1653-1660.
9. Wang, B, He, J, Liu, C and Chang, LJ (2006). An effective cancer vaccine modality lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 24: 3477-3489.
10. Guardino, AE, Rajapaksa, R, Ong, KH, Sheehan, K and Levy, R (2006). Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. Cytotherapy 8: 277-289.
11. Wojtowicz-Praga, S (1997). Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 20: 165-177.
12. Gabrilovich, D (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4: 941-952.
13. Mapara, MY and Sykes, M (2004). Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22: 1136-1151.
14. + T cell populations lacking helper function. Nat Immunol 6 163-170.
15. Chen, X, He, J and Chang, L-J (2004). Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology 1: 37.
16. Srivastava, PK and Udono, H (1994). Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opini Immunol 6: 728-732.
17. Tamura, Y, Peng, P, Liu, K, Daou, M and Srivastava, PK (1997). Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117-120.
18. Meissner, M, Reichert, TE, Kunkel, M, Gooding, W, Whiteside, TL, Ferrone, S et al. (2005). Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome. Clin Cancer Res 11: 2552-2560.
19. + T cells in tumors from patients with eady-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772.
20. Liyanage, UK, Moore, TT, Joo, HG, Tanaka, Y, Herrmann, V, Doherty, G et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761.
21. Lopez, M, Aguilera, R, Perez, C, Mendoza-Naranjo, A, Pereda, C, Ramirez, M et al. (2006). The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. Immunobiology 211: 127-136.
22. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176: 1582-1587.
23. Beyer, M and Schultze, JL (2006). Regulatory T cells in cancer. Blood 108: 804-811.
24. + regulatory T cells in patients with multiple myeloma. Blood 107: 3940-3949.
25. Prabhala, RH, Neri, P, Bae, JE, Tassone, P, Shammas, MA, Allam, CK et al. (2006). Dysfunctional T regulatory cells in multiple myeloma. Blood 107: 301-304.
26. Tien, AH, Xu, L and Helgason, CD (2005). Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 65: 2947-2955.
27. + proportion in spleen of tumor-bearing BALB/c mice. J Transl Med 3: 5.
28. Bouvier M (2003). Accessory proteins and the assembly of human class I MHC molecules: A molecular and structural perspective. Mol Immunol 39: 697-706.
29. Williams, DB (2006). Beyond lectins: The calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 119: 615-623.
30. Mondino, A, Knoruts, A and Jenkins, MK (1996). The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 93: 2245-2252.
31. Kroning, H, Tager, M, Thiel, U, Ittenson, A, Reinhold, D, Buhling, F et al. (1997). Overproduction of IL-7, IL-10 and TGF-B 1 in multiple myeloma. Acta Haematol 98: 116-118.
32. Fiore, F, Nuschak, B, Peola, S, Mariani, S, Muraro, M, Foglietta, M et al. (2005). Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol 35: 1155-1163.
33. Wing, K, Fehervari, Z and Sakaguchi, S (2006). Emerging possibilities in the development and function of regulatory T cells. Int Immunol 18: 991-1000.
34. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118.
35. + regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci USA 99: 8213-8218.
36. Zhou, G, Drake, CG and Levitsky, HI (2006). Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628-636.
37. Dannull, J, Su, Z, Rizzieri, D, Yang, BK, Coleman, D, Yancey, D et al. (2005). Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633.
38. Kang, SJ and Cresswell, P (2002). Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1 d heavy chain. J Biol Chem 277: 44838-44844.
39. Wan, Y, Wu, Y, Zhou, J, Zou, L, Liang, Y, Zhao, J et al. (2005). Cross-presentation of phage particle antigen in MHC class II and endoplasmic reticulum marker-positive compartments. Eur J Immunol 35: 2041-2050.
40. Thurner, B, Roder, C, Dieckmann, D, Heuer, M, Kruse, M, Glaser, A et al. (1999). Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223: 1-15.
41. Chang, L-J, Urlacher, V, Iwakuma, T, Cui, Y and Zucali, J (1999). Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 6: 715-728.
42. Chang, L-J and Zaiss, A-K (2001). Self inactivating lentiviral vectors in combination with a sensitive Cre/loxP reporter system. In Walker, J (ed.). Methods in Molecular Medicine. Humana Press: New Jersey. pp. 367-382.
43. Zaiss, A-K, Son, S and Chang, L-J (2002). RNA 3′-readthrough of oncoretrovirus and lentivirus: Implications in vector safety and efficacy. J Virol 76: 7209-7219.
44. Sheehy, ME, McDermott, AB, Furlan, SN, Klenerman, P and Nixon, DF (2001). A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 249: 99-110.